Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BLEOMYCIN for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 7 adverse event reports in the FDA FAERS database where BLEOMYCIN was used for Diffuse large b-cell lymphoma refractory.

Most Reported Side Effects for BLEOMYCIN

Side Effect Reports % Deaths Hosp.
Off label use 656 9.5% 190 250
Febrile neutropenia 632 9.2% 85 349
Neutropenia 433 6.3% 56 169
Drug ineffective 395 5.7% 81 127
Pyrexia 291 4.2% 40 211
Product use in unapproved indication 280 4.1% 82 82
Pulmonary toxicity 263 3.8% 137 59
Thrombocytopenia 260 3.8% 55 119
Nausea 255 3.7% 21 152
Anaemia 252 3.7% 33 92
Vomiting 240 3.5% 27 147
Respiratory failure 232 3.4% 148 146
Second primary malignancy 230 3.3% 104 38
Disease progression 227 3.3% 54 28
Acute myeloid leukaemia 222 3.2% 118 62

Other Indications for BLEOMYCIN

Hodgkin's disease (2,573) Testis cancer (348) Product used for unknown indication (342) Non-hodgkin's lymphoma (215) Diffuse large b-cell lymphoma (171) Seminoma (152) Germ cell cancer (137) Testicular germ cell tumour (132) Lymphoma (122) Chemotherapy (120)

Other Drugs Used for Diffuse large b-cell lymphoma refractory

RITUXIMAB (667) EPCORITAMAB-BYSP (353) AXICABTAGENE CILOLEUCEL (336) BENDAMUSTINE (283) CYCLOPHOSPHAMIDE (226) POLATUZUMAB VEDOTIN (223) ETOPOSIDE (165) POLATUZUMAB VEDOTIN-PIIQ (158) GEMCITABINE (147) LENALIDOMIDE (143)

Related Pages

BLEOMYCIN Full Profile All Diffuse large b-cell lymphoma refractory Drugs BLEOMYCIN Demographics BLEOMYCIN Timeline